Advertisement

Toxicities in B‑cell non-Hodgkin lymphoma—new agents, new pitfalls

  • Thomas SpanbergerEmail author
review

Summary

Immunochemotherapy has long been the backbone of all treatment for B‑cell non-Hodgkin lymphoma. These therapies led to long-term disease control or even cure for some patients. However, these treatments also caused—sometimes severe—toxicities and deterioration of the quality of life. Novel agents targeting the B‑cell-receptor pathway and bcl2 have made great inroads in the treatment of mature lymphoid neoplasms. These new agents present themselves with a wide variety of new toxicities, which have to be taken into account when being administered to our patients. Hematological toxicities are very common. All new agents lead to various levels of immune suppression or immune modulation, which is often not easily quantifiable. Opportunistic infections such as progressive multifocal leukoencephalopathy, pneumocystis pneumonia, other mycotic infections, cytomegalovirus infections and pneumocystis pneumonia have been described, sometimes with fatal outcome. Ibrutinib shows increased risk of atrial fibrillation. It also increases the risk of bleeding, making the proper anticoagulatory management of patients developing atrial fibrillation under treatment a challenge. Idelalisib causes severe, sometimes fatal immune-mediated end-organ toxicities, especially colitis, pneumonitis, and transaminitis. Copanlisib leads to metabolic changes, namely episodes of hyperglycemia and arterial hypertension. Venetoclax has caused clinically significant tumor lysis syndrome. The introduction of a prolonged ramp-up phase of step wise dose escalation has decreased the rate of clinically significant tumor lysis syndrome. The drug also causes high rates of hematological toxicities, especially neutropenia.

Keywords

Ibrutinib Idelalisib Venetoclax Tumor lysis syndrome BTK inhibitor 

Notes

Conflict of interest

T. Spanberger declares that he has no competing interests.

References

  1. 1.
    Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA, editors. SEER cancer statistics review, 1975-2015. Bethesda: National Cancer Institute; 2018. based on November 2017 SEER data submission, posted to the SEER web site. https://seer.cancer.gov/csr/1975_2015.Google Scholar
  2. 2.
    Tilly H, Gomes da Silva M, Vitolo U, et al. Diffuse large B‑cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v116–v25.CrossRefGoogle Scholar
  3. 3.
    Schulz H, Bohlius J, Skoetz N, et al. Chemotherapy plus Rituximab versus chemotherapy alone for B‑cell non-Hodgkin’s lymphoma. Cochrane Database Syst Rev. 2007;  https://doi.org/10.1002/14651858.cd003805.pub2.CrossRefPubMedGoogle Scholar
  4. 4.
    Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507–16.CrossRefGoogle Scholar
  5. 5.
    Varughese T, Taur Y, Cohen N, et al. Serious infections in patients receiving Ibrutinib for treatment of lymphoid cancer. Clin Infect Dis. 2018;  https://doi.org/10.1093/cid/ciy175.CrossRefPubMedGoogle Scholar
  6. 6.
    Raisch DW, Rafi JA, Chen C, Bennett CL. Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA’s adverse event reporting system. Expert Opin Drug Saf. 2016;15(8):1003–11.CrossRefGoogle Scholar
  7. 7.
    Reinwald M, Silva JT, Mueller NJ, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (intracellular signaling pathways: tyrosine kinase and mTOR inhibitors). Clin Microbiol Infect. 2018;24(Suppl 2):S53–S70.CrossRefGoogle Scholar
  8. 8.
    Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125(16):2497–506.CrossRefGoogle Scholar
  9. 9.
    Rhodes J, Mato A, Sharman JP. Monitoring and management of toxicities of novel B cell signaling agents. Curr Oncol Rep. 2018;20(6):49.CrossRefGoogle Scholar
  10. 10.
    Vrontikis A, Carey J, Gilreath JA, Halwani A, Stephens DM, Sweetenham JW. Proposed algorithm for managing Ibrutinib-related atrial fibrillation. Oncology (Williston Park, NY). 2016;30(11):970–4–980–1, C3.Google Scholar
  11. 11.
    Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213–23.CrossRefGoogle Scholar
  12. 12.
    Jaglowski SM, Jones JA, Nagar V, et al. Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. Blood. 2015;126(7):842–50.CrossRefGoogle Scholar
  13. 13.
    Caron F, Leong DP, Hillis C, Fraser G, Siegal D. Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis. Blood Adv. 2017;1(12):772–8.CrossRefGoogle Scholar
  14. 14.
    Boriani G, Corradini P, Cuneo A, et al. Practical management of ibrutinib in the real life: focus on atrial fibrillation and bleeding. Hematol Oncol. 2018;  https://doi.org/10.1002/hon.2503.CrossRefPubMedGoogle Scholar
  15. 15.
    Gopal AK, Kahl BS, de Vos S, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370(11):1008–18.CrossRefGoogle Scholar
  16. 16.
    Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997–1007.CrossRefGoogle Scholar
  17. 17.
    Sehn LH, Hallek M, Jurczak W, Brown JR, Barr PM, Catalano J, Coutre SE, Furman RR, Lamanna N, Loïc Y, Zelenetz AD, Sharman JP, DeVos S, Adewoye AH, Yeonhee K, Flinn IW, Salles GA. A retrospective analysis of pneumocystis Jirovecii pneumonia infection in patients receiving Idelalisib in clinical trials. Blood. 2018;128(22):3705. http://www.bloodjournal.org/content/128/22/3705.Google Scholar
  18. 18.
    Greenwell IB, Ip A, Cohen JB. PI3K inhibitors: understanding toxicity mechanisms and management. Oncology (Williston Park, NY). 2017;31(11):821–8.Google Scholar
  19. 19.
    Coutré SE, Barrientos JC, Brown JR, et al. Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma. 2015;56(10):2779–86.CrossRefGoogle Scholar
  20. 20.
    Dreyling M, Santoro A, Mollica L, et al. Phosphatidylinositol 3‑kinase inhibition by Copanlisib in relapsed or refractory indolent lymphoma. J Clin Oncol. 2017;35(35):3898–905.CrossRefGoogle Scholar
  21. 21.
    Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17(6):768–78.CrossRefGoogle Scholar
  22. 22.
    Davids MS, Roberts AW, Seymour JF, et al. Phase I first-in-human study of Venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol. 2017;35(8):826–33.CrossRefGoogle Scholar
  23. 23.
    Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-Rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378(12):1107–20.CrossRefGoogle Scholar
  24. 24.
    Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with Venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311–22.CrossRefGoogle Scholar
  25. 25.
    Coiffier B, Altman A, Pui C‑H, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008;26(16):2767–78.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2018

Authors and Affiliations

  1. 1.1. Med. AbteilungWilhelminenspitalViennaAustria

Personalised recommendations